DavidM.FaleckMD

Gastroenterology • New York, NY

Inflammatory Bowel Disease

Attending Gastroenterologist

Join to view full profile

Dr. Faleck is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Faleck's full profile

Already have an account?

Office
160 East 53rd Street
New York, NY 10022

Education & Training

Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Gastroenterology, 2015 - 2018
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2012 - 2015
Albert Einstein College of MedicineClass of 2012
University of PennsylvaniaBA, Biology, Jewish Studies, summa cum laude, 2004 - 2008

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2015 - 2026
NJ State Medical License 2022 - 2025
CT State Medical License 2024 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

Member AOA, 2012
Member Phi Beta Kappa, 2007

Clinical Trials

Stool Transplant to Control Treatment-related Diarrhea Start of enrollment: 2021 May 10
Active, not recruiting
Phase 1

Publications & Presentations

PubMed

47 citations
Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.
Neil H. Segal, Andrea Cercek, Geoffrey Y. Ku, Abraham J. Wu, Andreas Rimner
Clinical Cancer Research. 2021-01-27
76 citations
Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
Tomer Adar, David Faleck, Saranya Sasidharan, Kelly C. Cushing, Nienke Z. Borren
Alimentary Pharmacology & Therapeutics. 2019-04-01
53 citations
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Neeraj Narula, Farhad Peerani, Joseph Meserve, Gursimran Kochhar, Khadija Chaudrey
The American Journal of Gastroenterology. 2018-09-01

Journal Articles

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Leah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Gursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature